Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer

OBJECTIVES:

- Determine the safety and toxicity of radiofrequency ablation in patients with
refractory or advanced pulmonary malignancies.

- Determine the efficacy of this treatment, in terms of local control, in these patients.

- Determine whether CT scan is a reasonable imaging assessment tool for treatment
delivery and follow-up in these patients.

OUTLINE: Patients undergo percutaneous CT-guided radiofrequency ablation directly to the
tumor over 2 hours.

Patients are followed at 1, 3, 6, and 12 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

Inclusion Criteria:

- Diagnosis of a primary or secondary intrathoracic malignancy

- Any cell type or origin

- Involving the intrapulmonary, mediastinal, or pleural/chest wall

- Inoperable primary or metastatic cancer to the lung

- Refractory to or not amenable to conventional therapy (e.g., surgery, chemotherapy,
or radiotherapy)

- Single or multiple lesions that are non-contiguous with vital structures or organs
such as:

- Trachea

- Heart

- Aorta

- Great vessels

- Esophagus

- Less than 5 cm in largest dimension

- Accessible via percutaneous transthoracic route

- Hepatic:

- Coagulation profile normal